about
Antibodies to watch in 2015A decade of the Fast Track programmeAntibodies to watch in 2010New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.Monoclonal antibodies in the clinic.Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Development trends for monoclonal antibody cancer therapeutics.Development trends for new cancer therapeutics and vaccines.Antibodies to watch in 2016.Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CAAntibodies to watch in 2017Note of appreciation to reviewers.Trends in US approvals: new biopharmaceuticals and vaccines.Recombinant protein therapeutics--success rates, market trends and values to 2010.Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.Global antibody development trends.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.Marketing approval of mogamulizumab: a triumph for glyco-engineering.IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.Metrics for antibody therapeutics development.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAEuropean Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UKAntibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.Antibodies to watch in 2013: Mid-year update.6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.The amazing, multipurpose antibody.Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Letter from the Editor: stratified medicine.Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies.mAb therapeutic products and risk management.Americas Antibody Congress: September 21-23, 2009, Washington, D.C.Bispecific antibodies and ADCs: Once and future kings?Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA.4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.
P50
Q28253501-A29B5027-67D2-4569-8281-23D9195A68AFQ28298489-EB041BCB-A788-4953-9C69-7EA18CD83E31Q33688243-39B57B90-EEA6-48A9-99A7-D56E3E2C5F83Q34003201-2220A8E7-D14E-4455-AC25-08ACAC98BCAEQ34354268-81CB07A2-70BA-4375-85A1-42CDF9F1E2F0Q35933820-FB12EBE4-A6FA-478C-88BC-98CB1FEA44FBQ35992488-A9F7F96B-219C-460E-BDA1-02FB8854763EQ35992493-C6424C31-6013-4DA5-B2CE-D0F41ACE2507Q36790534-A57317A5-4CD4-4478-ABD5-DABDC37A2173Q37055390-A6852E9B-E745-4562-A54E-264E47F756EDQ37138505-735901D5-EC6C-4B39-A4E2-35136EB1CCC0Q37397677-EECA8D51-3363-4930-A7FB-65C19BFC1319Q37631319-0E737C2D-12AA-407E-9032-00E66B4B3F6DQ38986169-99003592-1F51-4FE0-9B04-BED96B321B8EQ40318335-4E0B25A0-EDBA-44C5-9447-31AA072E8A15Q40462810-D3330733-783E-4DC2-9EE4-71553DFC4FDDQ40644061-A8F84EDB-BC03-48E0-A2E7-8EAB626D906AQ41791312-9107A6B2-20E7-480D-B5CB-027C7FA34445Q42333450-BD960EDA-699A-4246-90D0-248FD17C7213Q42333453-015FCF67-6DF6-4B15-B8CF-5ED5F2DFEDF3Q42337747-02F4D1B5-8BCD-4AE6-A0D2-91D38360394FQ42394071-34E6A344-0877-49CA-96D8-EF9523D5CDAAQ42556144-25D6F6F4-E1BD-4B4B-B765-A3351BCC7F59Q42557137-8B4AD1D0-4BBE-4E67-967A-EFC2F6B9DDD3Q42580265-1FC7433E-B6A8-425D-88D3-661D1C363454Q42600840-0B343A75-81E8-434C-B26C-838A21547243Q42724515-958E7338-D1AE-4404-91C1-417E9EF364F3Q42732008-22D4F483-5299-44A4-A9E9-138CF891FC94Q42732010-A01F5B81-7E45-4FC4-9FA1-6D9FAE445046Q42846272-BBF8F4BC-4D92-4522-9549-CAC271FE310CQ42854232-60CC47EE-75AB-49A1-8A9E-9AD6EC4E112EQ42854233-8BF5D733-C8EE-4670-979E-84CBDA2E9A06Q42869354-E59689C7-246B-4E01-BDFD-AC4F654BE315Q42869356-EE7EBA41-A53C-43C6-88E1-6204CAFA043EQ42871386-A21AB92F-6103-4280-9F33-B36817E410EDQ42906686-38D08892-5B2D-479E-9164-8A5642872B1DQ42957194-5FAE13B6-90AE-4CCF-917D-C40388BD461FQ42972046-469AEA27-6BF2-49E6-BB08-D7B38B425936Q43070193-DB0DD140-E202-4254-B4F4-5C3E56542C0DQ43072108-EB97AD09-BC66-4952-96BD-E7EE4520C055
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Janice M Reichert
@es
Janice M. Reichert
@en
Janice M. Reichert
@nl
Janice M. Reichert
@sl
type
label
Janice M Reichert
@es
Janice M. Reichert
@en
Janice M. Reichert
@nl
Janice M. Reichert
@sl
prefLabel
Janice M Reichert
@es
Janice M. Reichert
@en
Janice M. Reichert
@nl
Janice M. Reichert
@sl
P106
P1153
7102454463
P21
P31
P496
0000-0003-0400-1951
P569
2000-01-01T00:00:00Z